Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (31-40 of 635) with videos related to

Pageof 64
Sort By:
Cardiology and Therapy|June 23, 2022
Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor AntagonistSrikanth Palanisamy, Mario Funes Hernandez, Tara I Chang, et al.
American Heart Journal|December 9, 2003
Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategiesRichard E Waters, Kenneth W Mahaffey, Christopher B Granger, et al.
Diabetes, Obesity & Metabolism|April 9, 2020
Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEYJinnie J Rhee, Meg J Jardine, Glenn M Chertow, et al.
Cardiovascular Diabetology|April 29, 2023
Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCEGiulia Ferrannini, Carol Pollock, Andrea Natali, et al.
Biostatistics (Oxford, England)|August 28, 2010
Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trialMin Zhang, Anastasios A Tsiatis, Marie Davidian, et al.
American Heart Journal|March 8, 2017
Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trialVictoria M Robinson, David B Bharucha, Kenneth W Mahaffey, et al.
Diabetes, Obesity & Metabolism|August 31, 2021
Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trialMatthew R Weir, Jagadish Gogate, C V Damaraju, et al.
Cardiology and Therapy|August 16, 2024
Milvexian: An Oral, Bioavailable Factor XIa InhibitorShyon Parsa, Sneha S Jain, Olu Akinrimisi, et al.
American Heart Journal|August 30, 2005
A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromesRobert M Califf, John L Petersen, Vic Hasselblad, et al.
JAMA Internal Medicine|February 26, 2019
Characteristics of Digital Health Studies Registered in ClinicalTrials.govConnie E Chen, Robert A Harrington, Sumbul A Desai, et al.
Pageof 64

Showing results (31-40 of 635) with videos related to

Sort By:
Pageof 64
Cardiology and Therapy|June 23, 2022
Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor AntagonistSrikanth Palanisamy, Mario Funes Hernandez, Tara I Chang, et al.
American Heart Journal|December 9, 2003
Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategiesRichard E Waters, Kenneth W Mahaffey, Christopher B Granger, et al.
Diabetes, Obesity & Metabolism|April 9, 2020
Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEYJinnie J Rhee, Meg J Jardine, Glenn M Chertow, et al.
Cardiovascular Diabetology|April 29, 2023
Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCEGiulia Ferrannini, Carol Pollock, Andrea Natali, et al.
Biostatistics (Oxford, England)|August 28, 2010
Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trialMin Zhang, Anastasios A Tsiatis, Marie Davidian, et al.
American Heart Journal|March 8, 2017
Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trialVictoria M Robinson, David B Bharucha, Kenneth W Mahaffey, et al.
Diabetes, Obesity & Metabolism|August 31, 2021
Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trialMatthew R Weir, Jagadish Gogate, C V Damaraju, et al.
Cardiology and Therapy|August 16, 2024
Milvexian: An Oral, Bioavailable Factor XIa InhibitorShyon Parsa, Sneha S Jain, Olu Akinrimisi, et al.
American Heart Journal|August 30, 2005
A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromesRobert M Califf, John L Petersen, Vic Hasselblad, et al.
JAMA Internal Medicine|February 26, 2019
Characteristics of Digital Health Studies Registered in ClinicalTrials.govConnie E Chen, Robert A Harrington, Sumbul A Desai, et al.
Pageof 64